Markers Supplementing CA 125 in Ovarian Cancer
| Autor: | Ulf-Håkan Stenman, Juhani Vartiainen, Henrik Alfthan, Pentti Lehtovirta |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Ovarian Neoplasms
endocrine system medicine.medical_specialty Trypsin inhibitor Mucin CA 15-3 Ovary General Medicine Biology Prognosis medicine.disease Sensitivity and Specificity Procollagen peptidase medicine.anatomical_structure Endocrinology CA-125 Antigen Internal medicine Biomarkers Tumor medicine Cancer research Humans Female Ovarian cancer Alpha-fetoprotein Germ cell |
| Zdroj: | Annals of Medicine. 27:115-120 |
| ISSN: | 1365-2060 0785-3890 |
| DOI: | 10.3109/07853899509031946 |
| Popis: | Markers supplementing CA 125 are important for monitoring of the disease in patients with mucinous and non-epithelial ovarian cancers. Tumour-associated trypsin inhibitor (TATI) or one of the gastrointestinal mucin markers, CA 19-9 or CA 72.4 are good supplements to CA 125 in mucinous ovarian cancer. Chorionic gonadotrophin (hCG) and alpha fetoprotein (AFP) are the most useful markers for germ cell tumours, and hCG beta may provide additional information. In addition to hCG beta, M-CSF and inhibin show promise of becoming useful supplements to CA 125 in ovarian cancer in general. Markers other than CA 125 may also play a role as prognostic indicators. TATI and procollagen peptides appear useful for this purpose. If these markers prove to provide reliable prognostic information, they could be used to aid selection of optimal treatment regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|